5-Year Real-World Outcomes with Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC.
CLINICAL LUNG CANCER（2024）
Key words
Advanced nonsmall cell lung cancer,Overall survival,Immunotherapy,Real-world time on treatment,Subsequent therapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined